Developing novel blood-based cancer diagnostic assays | CEO @ForesightDx | former PhD @StanfordMed | #ctdna #LiquidBiopsy #MRD
Denver, CO
Joined January 2020
- Tweets73
- Following162
- Followers284
- Likes170
Jake Chabon retweeted
We are presenting four oral presentations and two posters at #ASH23, with new data on PhasED-Seq's earlier and more accurate MRD detection vs. PET/CT.
It’s time to rethink response assessment in clinical trials.
prnewswire.com/news-releases…
#ASH23
Jake Chabon retweeted
We are excited to announce that we closed an oversubscribed Series B financing round of $58.75M. The financing was led by @ForesiteCapital with participation from @CivilizationVC , @BluebirdLifeSci, @pearvc , @agent_capital, @Stanford, @CUSystem.
foresight-dx.com/news/foresi…
Jake Chabon retweeted
I told the founding team at @ForesightDx that we’re builders at @CivilizationVC. And I meant it! :)
Awesome new offices in Colorado.
Ready to conquer #Cancer thru better #diagnostics
@AshAlizadeh @JakeChabon @max_diehn
@themasap
Jake Chabon retweeted
Detect a potential cancer relapse 200 days sooner. The PhasED-Seq platform detects residual tumor DNA at levels below current testing: nature.com/articles/d43747-0…
#cancer #tumor #lymphoma #LiquidBiopsy #relapse
ALT Foresight Dx | technical advances in MRD detection in a recent article in Nature Biopharma Dealmakers.
Jake Chabon retweeted
We were recently chosen to take part in a NSCLC research summit with AstraZeneca and wanted to share some relevant data about our work in lung cancer.
Check out the poster originally presented at ASCO last year: foresight-dx.com/documents/K…
#NSCLC #liquidbiopsy #MRD
Jake Chabon retweeted
Our PhasED-Seq #ctDNA liquid biopsy strongly correlates with standard of care CT imaging in #DLBCL patients and remarkably identifies treatment response to acalabrutinib in only 7 days.
Read the #ASH21 abstract (524) here: bit.ly/3mLUvXn
@AshAlizadeh
Jake Chabon retweeted
Our PhasED-Seq #ctDNA platform’s transformative potential to improve #MRD detection, along with research led by our co-founder Dr. David Kurtz, was the subject of @landau_lab and @AlexandrePCheng’s recent review paper in Med.
Read more: bit.ly/3BMIc29
Jake Chabon retweeted
We’re honored to be named a finalist for the CBSA Rising Star award and look forward to seeing members of the Colorado life science community at the 2021 Colorado BioScience Innovation Forum and Annual Awards Celebration.
bit.ly/3nN2B2G
#CoBioScience @cobioscience
Jake Chabon retweeted
.@CLPmag featured us in a deep dive on PhasED-Seq, our #ctDNA #MRD detection platform. Co-founder/CEO, @JakeChabon PhD discusses PhasED-Seq’s superior sensitivity over existing #LiquidBiopsy assays and its potential to improve B cell #lymphoma management.
bit.ly/3AtqvnF
Jake Chabon retweeted
A major advance in 1st line #DLBCL care and the first in 20 years was reported in the POLARIX trial showing improved PFS vs. standard of care. Along with our PhasED-Seq #ctDNA platform that detects #MRD, we are improving the lives of #lymphoma patients.
bit.ly/3fUc7fH
POLARIX study meets primary endpoint. Press release: R-CHP+Pola had superior investigator assessed PFS compared with R-CHOP in 1st line high risk DLBCL.
A new standard of care in DLBCL? Has R-CHOP really been beaten? Can’t wait to see the data! #lymsm
roche.com/de/media/releases/…
Jake Chabon retweeted
Delighted to share our new study nature.com/articles/s41587-0… introducing PhasED-Seq out today @NatureBiotech.
Jake Chabon retweeted
Foresight co-founders @max_diehn MD/PhD and @AshAlizadeh MD/PhD in @GenomeWeb explain what differentiates PhasED-Seq from existing #MRD approaches as well as future #PrecisionMedicine applications our #ctDNA platform could enable.
Access the article here: bit.ly/3y9csCj
Jake Chabon retweeted
We have been featured in a story by @BioWorldMedTech. Our co-founder and CEO, @JakeChabon, discusses findings from our recent @NatureBiotech publication and the potential of our PhasED-Seq #ctDNA platform in cancer surveillance and diagnostics.
This Post is from an account that no longer exists. Learn more
Jake Chabon retweeted
We are presenting exciting new data on the performance of our #MRD platform in #DLBCL patients at @icmlugano this Sunday. The talk will introduce PhasED-Seq, our proprietary technology that enables #ctDNA detection down to parts-per-million levels! businesswire.com/news/home/2…
Jake Chabon retweeted
Presentations describing Foresight's novel #ctDNA assay for #MRD detection in #lymphoma (Abstract #7565) and #lungcancer (Abstract #8518) are live at #ASCO21! If redirected, try opening the link in an incognito window.
meetinglibrary.asco.org/reco…
meetinglibrary.asco.org/reco…
Jake Chabon retweeted
Finally we can reveal this!
100-times more sensitive than existing liquid biopsy approaches which improves the lives of cancer patients.
We are so excited to announce our investment in Foresight!
@ForesightDx @CivilizationVC @BluebirdLifeSci @pearvc
Excited to come out of stealth and announce our $12.5M #SeriesA financing! We’re on a mission to improve the lives of cancer patients with our novel #LiquidBiopsy #MRD testing platform.
Thanks to our investors @CivilizationVC @BluebirdLifeSci & @pearvc.
prnewswire.com/news-releases…
Jake Chabon retweeted
So excited to share our new model of #ctDNA shedding for #cancerearlydetection doi.org/10.1126/sciadv.abc43… @ScienceAdvances @CanaryCenter @StanfordRad @StanfordCancer @BdsStanford @StanfordMed 1/n
Jake Chabon retweeted
Thrilled our paper showing KEAP1/NFE2L2 mutations predict for radiation resistance in NSCLC which may be overcome by glutaminase inhibition is in press (cancerdiscovery.aacrjournals…). Grateful for mentorship by @max_diehn and all coauthors including Dr. Jeon. Towards precision RT
Jake Chabon retweeted
Excited to present 'EPIC-Seq', a new technique for cancer detection & COO classification from epigenetic information in #cfDNA at #AACR2020! Register for free and drop in on June 23 at 9:50 AM (EDT) to hear about it. abstractsonline.com/pp8/#!/9…
AACR Virtual Annual Meeting II kicks off Monday, Follow the meeting via #AACR20 for the latest groundbreaking science, plus highly relevant talks on COVID-19 and health inequities and disparities. bit.ly/2AUnH9m
Jake Chabon retweeted
SCI trainee @everettmoding and colleagues developed a mid-chemoradiation dynamic risk model integrating tumor features and ctDNA analysis for #lungcancer outcome prediction that may identify patients at very high and low risk of progression. bit.ly/2zEQlL0 #ASCO20
